The efficacy and safety of pioglitazone in psoriasis vulgaris
A meta-analysis of randomized controlled trials

Pengfei Chen, MDª, Xiubing Chen, MMª, Lei Lei, MDª, Yang Zhang, MDc, Jianjun Xiang, MDb,∗, Jinxia Zhou, MDb,†, Jun Lv, MDc,†

Abstract
Pioglitazone may have potential benefits in the treatment of cutaneous and metabolic derangements of psoriasis, but its role in the treatment of psoriasis remains in debate. We therefore conducted a meta-analysis to evaluate the clinical efficacy and safety of pioglitazone in psoriasis vulgaris (PsV).

We performed a comprehensive search in database of PubMed, Web of Science, Cochrane library, Embase and China National Knowledge Infrastructure (CNKI), and Wan fang database through March 2019 to identify eligible studies. Randomized controlled trials that have evaluated the effect and safety of pioglitazone in PsV were included. Treatment success was defined as ≥75% reduction in psoriasis area and severity index (PASI) score after treatment. Weighted mean differences (WMD), relative risks (RRs) and the corresponding 95% confidence intervals (CIs) were pooled to compare the clinical efficacy and safety between different groups.

Six randomized controlled trials (n = 270) were included. Meta-analysis showed that pioglitazone was associated with a remarkable reduction in PASI score in patients with PsV (weight mean difference: 2.68, 95% CI 1.41–3.94, P < .001). The treatment success rate in the pioglitazone group was higher than in the control group (RR 3.60, 95 CI 1.61–8.01, P < .001). Compared with control group, pioglitazone was not related to a pronounced increase in total adverse events (RR 1.180, 95 CI 0.85–1.63, P = .33). Moreover, the risk of common adverse events in the 2 groups were similar, such as elevated liver enzyme, fatigue, nausea, weight gain.

This meta-analysis suggested pioglitazone is an effective and safe drug in the treatment of patients with PsV.

Abbreviations: CIs = confidence intervals, PPARs = proliferator-activated receptors, PRISMA = Preferred Reporting Items for Systematic Review and Meta-analysis, PsV = psoriasis vulgaris, RRs = relative risks, TZDs = thiazolidinediones.

Keywords: pioglitazone, psoriasis vulgaris, meta-analysis

1. Introduction
Psoriasis is a chronic inflammatory skin disease that shares similar pathogenic mechanism with other inflammatory disorders such as metabolic syndrome, insulin resistance and cardiovascular events. The global prevalence of psoriasis is 2% to 3%, which also affects about 0.4% of Asians. Chronic psoriasis vulgaris (PsV) accounts for proximately 90% of the psoriasis cases. Although the pathological process of PsV is unclear, it contributes to the development of various systemic diseases. Also, patients with PsV show high rates of remissions and relapses that require repeated and prolonged of therapy though-out life, resulting in poor quality of life and mental health. Traditional treatments for PsV include methotrexate, acitretin, cyclosporine, and photochemotherapy; however, these drugs have potential...
risks of serious toxic effects, such as liver and kidney toxicity, carcinogenesis, and teratogenesis during long-term use, which limits their clinical application.\textsuperscript{[5,6]}

Pioglitazone is a representative of the thiazolidinediones (TZDs) drug known in diabetes and dyslipidemia, with no serious side effects in short-term use.\textsuperscript{[7,8]} It works by binding to the proliferator-activated receptors (PPARs) that regulate carbohydrate and lipid metabolism.\textsuperscript{[9]} PPARs are expressed on epidermal keratinocytes, and activation of these receptors has been shown to inhibit the proliferation of psoriatic human keratinocytes in vitro. Some researches reported that TZDs may improve psoriasis by increasing insulin sensitivity and anti-proliferative effects.\textsuperscript{[10,11]} Based on the pro-differentiating and anti-proliferative effects on keratinocytes, pioglitazone may have potential benefits in the treatment of cutaneous and metabolic derangements of psoriasis.\textsuperscript{[12,13]} However, there limited clinical studies focusing on the clinical application of pioglitazone in psoriasis, and their results remain inconsistent. Therefore, we performed a meta-analysis to determine the role of pioglitazone in the treatment of PsV.

2. Materials and methods

2.1. Literature research

The PRISMA protocol was followed in our meta-analysis.\textsuperscript{[14]} We performed a comprehensive search in database of PubMed, Web of Science, Cochrane library, Embase and China National Knowledge Infrastructure (CNKI), and Wanfang database through March 2019 to identify eligible studies, using the search terms as follows: “pioglitazone” OR “thiazolidinedion” OR “TZD” AND “psoriasis.” Additionally, manual search of the references in relevant reviews and meta-analyses was performed to find potentially eligible supplements.

2.2. Criteria for inclusion

Studies in patients with PsV were included if they met all of the following conditions:

1. randomized controlled trials with a blind design or not;
2. with a sample size of at least 20 patients;
3. have a clinical follow-up duration >4 weeks;
4. have reported the outcomes we focused on, including psoriasis area and severity index (PASI) scores, therapeutic efficacy, and adverse events;
5. therapeutic efficacy was defined as a reduction in PASI score after treatment ≥75%.

Articles were excluded if they were reviews, comments, abstracts, and duplicates.

2.3. Data collection and quality assessment

Two independent reviewers extracted the details on study and patients characteristics, including the author, year of publication, sample size, age, gender, intervention, observation time, and outcome data. The quality of the included studies was assessed by using the Cochrane collaboration’s tool for assessing the risk of bias,\textsuperscript{[15]} which mainly includes six domains: random sequence generation, allocation concealment, binding of participants and personnel, binding of outcomes, incomplete outcome data, and selective reports. Any disagreements between the 2 reviewers were handled by consulting with a third reviewer.

2.4. Statistical methods

We used risk ratios (RRs) and weight mean difference (WMD) and their corresponding 95% confidence intervals (CIs) to report the pooled risk estimates, which were assessed by random effects model. The heterogeneity across studies was examined under Cochrane Q test with a significant value of $P < .1$ and quantified by ${I}^2$ statistics, and a value of $I^2 > 50\%$ was considered as significant heterogeneity. A sensitivity analysis was conducted by omitting each study in sequence. Publication bias was detected by using the Egger’s test.\textsuperscript{[16]} All statistical analyses were performed using Review Manager 5.2 (RevMan, The Nordic Cochrane Center, The Cochrane Collaboration, 2012) and STATA 11.2 software (Stata Corp, College Station, TX), and $P$ values < .05 were considered significant.

2.5. Ethics statement

This study was a secondary analysis of human subject data published in the public domain, thus no ethical approval was needed.

3. Results

3.1. Literature research

The search strategy initially identified 86 publications, of which 29 duplicates and 42 irrelevant studies were removed after scanning the titles and abstracts. The remaining 15 studies were selected for full-text reading, and 9 articles failed to meet the recruitment criteria. Finally, 6 studies\textsuperscript{[3,9,12,17–19]} were included in this meta-analysis (Fig. 1).

3.2. Study characteristics

The main characteristics of the include studies are displayed in Table 1. Briefly, the included studies consist of 270 participants, of which 135 participants were in the pioglitazone group and 135 participants were in the control group. The number of enrolled patients ranged from 16 to 30, with patients’ age varying from 18 to 70 years, and male accounted for 68.9% of the total participants. All studies have reported the PASI, and 5 studies have provided the data about treatment success rate, with follow-
up durations ranging from 10 to 16 weeks. None of the included studies showed a high risk of bias according to the Cochrane tool (Supplementary Figure 1, http://links.lww.com/MD/E671).

3.3. Outcome of efficacy meta-analysis
Pooled analyses for change in PASI are displayed in Figure 2. The pooled WMD (95%CI) of PASI change was 2.68 (1.41–3.94) for pioglitazone group vs control group (Fig. 2), with no significant heterogeneity across the studies ($I^2 = 5\%$, $P = .38$). Five studies have reported the treatment success rate, totaling 246 participants. The treatment success rate was 58.6% (65/111) and 17.4% (21/121), respectively, in the pioglitazone group and control group. The pooled RR (95%CI) of the treatment success event was 3.60 (1.61–8.01) for pioglitazone group vs control group (Fig. 3), with significant heterogeneity across the study ($I^2 = 59\%$, $P = .05$). We performed a subgroup analysis between the pioglitazone only therapy and pioglitazone combined therapy. The outcome of efficacy also showed pioglitazone has a beneficial effect in PsV and pioglitazone combined therapy had more effective than methotrexate, phototherapy or acitretin medicine for PsV (Supplemental Figures 2 and 3, http://links.lww.com/MD/E672 and http://links.lww.com/MD/E673).

3.4. Outcome of safety meta-analysis
The pooled RR (95%CI) of total adverse event was 1.18 (0.85–1.63) for pioglitazone group versus control group (Fig. 4), with no significant heterogeneity across the study (n = 2, $I^2 = 0\%$, $P = .84$). Only 1 study reported$^{31}$ a case of myocardial infarction that occurred in the control group, and none of the remaining studies reported any serious adverse events or hypoglycemia events. In addition, the common adverse events in the pioglitazone group and the control group were not significant different, such as elevated liver enzymes (n = 2, $I^2 = 0\%$, $P = .99$; RR 3.06, 95%CI 0.33–28.39), fatigue (n = 2, $I^2 = 0\%$, $P = .48$; RR 0.46, 95%CI 0.12–1.72), nausea (n = 3, $I^2 = 0\%$, $P = .92$; RR 0.68, 95%CI 0.20–2.29), weight gain (n = 5, $I^2 = 0\%$, $P = .82$; RR 0.91, 95%CI 0.60–1.37) (Fig. 4).

3.5. Sensitivity analysis and publication bias
Sensitivity analysis by excluding individual study in sequence had no significant influence on the efficacy and safety outcomes. Publication bias was assessed using the data of change in PASI, treatment success event and weight gain. The results showed that there was no evidence of publication bias for these measurements (Egger’s test: $P = .65$, $P = .11$, $P = .15$, respectively).

4. Discussion
Our meta-analysis of 6 randomized trials showed that pioglitazone has a beneficial effect in PsV, as shown by the remarkable reduction in PASI score and enhanced treatment success rate. Moreover, the adverse event was not increased compared with the control group. To the best of our knowledge, this is the largest meta-analysis of RCTs using pioglitazone for treatment of PsV. A previous systematical review of 2 studies showed that pioglitazone appears to have efficacy for the treatment of psoriasis.$^{20}$ However, their findings were limited by insufficient data and no use of adverse data.

TZDs were the first introduced in the late 1990s, and now are widely used in patients with type 2 diabetes. Recently, nondiabetic effects, such as blood-pressure lowering and fibrinolytic effects, have been demonstrated for TZDs.$^{21}$ From a mechanistic view, TZDs are ligands of PPAR-γ that expressed...
in many types of cells including epidermal keratinocytes.\textsuperscript{[11,22]} The PPAR-\(\gamma\) agonists regulate anti-inflammatory actions by decreasing the levels of inflammatory cytokines like IL-2, TNF-\(\alpha\), and IFN-\(\gamma\), and downregulating the expression of adhesion molecules like VCAM-1.\textsuperscript{[23]} IL-17 is the production of T helper type 17 (Th17) cells, Liu et al reported PPAR-\(\gamma\) agonist pioglitazone administration suppressed the production of pro-inflammatory cytokines like IL-17, TNF-\(\alpha\) and down-regulated
the mRNA expression levels of inflammatory mediators to treat the intervertebral disc degeneration.[24] Disordered cellular including inflammatory cytokines has been indicated in the pathogenesis of psoriasis.[23] PPARs have three members of transcription factors (α, β, γ) that were the nuclear hormone receptors superfamily.[25] These receptors may function important in dermatologic diseases, and the mechanism may be associated with hyperproliferation and aberrant differentiation of the keratinocytes.[26,27] Bhagavathula et al demonstrated rosiglitazone (a potent TZD) inhibited both proliferation and motility as well as elaboration of MMP-1 and MMP-9, thus contributing to the phenotype of psoriatic lesional skin in vitro.[28] Glucocorticoids, vitamin D₃, and retinoids play a key role on nuclear hormone receptors with a beneficial effect in the development of antipsoriatic drugs.[19] El-Gharabawy et al reported the activation of PPAR-γ receptors by pioglitazone results in reduced formation of the proinflammatory cytokines and infiltration of the inflammatory cells, indicating the beneficial effects of pioglitazone in treatment of psoriasis.[10] Moreover, our meta-analysis of 6 randomized trials indicated that pioglitazone has a beneficial effect in PsV, as reflected by the improved PASI and treatment success rate. Some studies implied the rosiglitazone was related to an increased risk of cardiovascular death and heart attack, but pioglitazone seems not to share this risk. Therefore, patients and providers should consider the potential of serious adverse cardiovascular effects when using rosiglitazone for type 2 diabetes.[20,30,31] Graham et al have reported that rosiglitazone but not pioglitazone was associated with an increased risk of AMI, stroke, heart failure, or all-cause mortality.[22] TZDs are known to result in elevation liver enzymes, weight gain, fatigue, nausea, and dyslipidemia.[23] However, our meta-analysis did not find any serious adverse events associated with pioglitazone, and pioglitazone did not increase the risk of common adverse events, indicating the safety for the patients with PsV.

There are some limitations in our study. First, all included trials had a small sample size that may result in insufficient statistical power. Secondly, there are some differences in the baseline characteristics of patients, such as disease severity and adjunctive treatment, which may lead to the statistical heterogeneity of the pooling results. Thirdly, the follow-up durations of patients were <4 months; thus, it is unclear that whether pioglitazone could improve the long-term outcomes of psoriasis.

In conclusion, the current meta-analysis of 6 randomized controlled trials totaling 270 participants had revealed that pioglitazone is an effective and safe drug in the treatment of patients with PsV. Further studies with larger sample sizes, longer follow-ups, and diverse populations are needed to confirm our result.

Author Contributions

Conceptualization: Pengfei Chen.
Data curation: Xiubing Chen.
Formal analysis: Jinxia Zhou, Lei Lei.
Investigation: Jianjun Xiang.
Methodology: Yang Zhang, Xiubing Chen, Jun Lv.
Software: Pengfei Chen.
Visualization: Jun Lv.
Writing – original draft: Pengfei Chen.
Writing – review & editing: Jun Lv.

References

[1] Boehncke WH, Sterry W. Psoriasis—a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives. J Dtsch Dermatol Ges 2009;7:946–52.
[2] Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321–8.
[3] Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination Atretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009;145:887–93.
[4] Dressler C, Lambert J, Grie L, et al. Therapeutic patient education and self-management support for patients with psoriasis - a systematic review. J Dtsch Dermatol Ges 2019;17:685–95.
[5] Andersen YMF, Wu J, Thyssen JP, et al. Chronological order of appearance of immune mediated inflammatory diseases relative to diagnosis of psoriasis. J Am Acad Dermatol 2019;81:1283–91.
[6] Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open 2019;9:e027535.
[7] Ip W, Kirchhof MG. Glycemic control in the treatment of psoriasis. Dermatology 2017;233:23–9.
[8] El-Gharabawy RM, Ahmed AS, Al-Najjar AH. Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis. Biomed Pharmacother 2017;85:141–7.
[9] Ghiasi M, Ebrahim M, Lajevardi V, et al. Efficacy and safety of pioglitazone plus phototherapy vs. phototherapy in patients with plaque type psoriasis: a double blinded randomized controlled trial. J Dermatol Treat 2018;1–5.
[10] Boyd AS. Thiazolidinediones in dermatology. Int J Dermatol 2007;46: 537–63.
[11] Friedmann PS, Cooper HL, Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm Venereol 2005;85:194–202.
[12] Lajevardi V, Hallaji Z, Dakhlan S, et al. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol 2015;54:95–101.
[13] Luconi M, Cantini G, Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer? Steroids 2010;75:585–94.
[14] Hutton B, Salants G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84.
[15] Wieland LS, Mantheiner E, Berman RM. Development and classification of an operational definition of complementary and alternative medicine for the Cochrane collaboration. Altern Ther Health Med 2011;17:50–9.
[16] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
[17] Hafetz VG, Bossela M, Abdel Halim MR, et al. Clinical effects of “pioglitazone”, an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trial1. J Dermatol Treat 2015;26:208–14.
[18] Shaqiq N, Malhotra S, Pandhi P, et al. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005;44:328–33.
[19] Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol 2016; 16:12.
[20] Malhotra A, Shaqiq N, Rajagopalan S, et al. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med 2012;17:171–6.
[21] Yasin S, Jayaprakash V. Thiazolidinediones and PPAR orchestra as antidiabetic agents: from past to present. Eur Med Clin 2017;126: 879–93.
[22] Yi W, Shi J, Zhao G, et al. Identification of a novel selective PPARgamma ligand with a unique binding mode and improved therapeutic profile in vitro. Sci Rep 2017;7:41487.
[23] Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antinflammatory mediators in human T lymphocytes: implications for
atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002;90:703–10.

[24] Liu Y, Qu Y, Liu L, et al. PPAR-gamma agonist pioglitazone protects against IL-17 induced intervertebral disc inflammation and degeneration via suppression of NF-kappaB signaling pathway. Int Immunopharmacol 2019;72:138–47.

[25] Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263–71.

[26] Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 2017;13:36–49.

[27] Mossner R, Schulz U, Kruger U, et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 2002;119:576–82.

[28] Takada I, Makishima M. PPARgamma ligands and their therapeutic applications: a patent review (2008-2014). Expert Opin Ther Pat 2015;23:175–91.

[29] Bhagavathula N, Nerusu KC, Lal A, et al. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol 2004;122:130–9.

[30] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.

[31] Lee EJ, Marcy TR. The impact of pioglitazone on bladder cancer and cardiovascular events. Consult Pharm 2014;29:555–8.

[32] Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411–8.

[33] Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605–11.